PPARG and diabetic kidney disease: In support of our findings, peroxisome proliferator‐activated receptor gamma (PPAR‐γ) agonist ciglitazone can protect DKD in part by activating PPAR‐γ and clearing glomerular tissue homocysteine.32 Pending prospective reproducible investigations circulating homocysteine concentrations can help identify diabetic patients with a high risk of DKD who could benefit from closer monitoring.